Quinoa Effects on Glycemic Index and Satiety

Not Applicable

Completed

• Conditions: Overweight
• Interventions: Dietary Supplement: Anhydrous Glucose; Dietary Supplement: Quinoa variety 1; Dietary Supplement: Quinoa variety 3; Dietary Supplement: Quinoa variety 2; Dietary Supplement: Quinoa variety 4

• Registration Number: NCT02621502
• Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Brief Summary

The purpose of this study is to to assess the glycemic index and the satiating properties of different Quinoa varieties, using a Visual Analogue Scale in a sample of healthy overweight subjects.

Detailed Description

Pilot study to evaluate the glycemic index, and the satiating effect using different Quinoa varieties in a group of healthy overweight subjects.

Study Timeline

• Study Start: 2014-09
• Primary Completion: 2014-12
• Study Completion: 2015-01
• Study First Submitted: 2015-11-18
• Status Verified: 2015-12
• Study First Submitted QC: 2015-12-01
• Last Update Submitted: 2015-12-01
• Study First Posted: 2015-12-03
• Last Update Posted: 2015-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Men and women from 18 to 65 years old.
• Body mass index (BMI) ≥25 and <30 kg/m2.
• Adequate cultural level and understanding for the clinical trial.
• Signed informed consent

Exclusion Criteria

• Individuals with BMI ≥30 or <25 kg/m2
• Vegetarians or individuals with a fiber intake ≥30 g/day
• Individuals diagnosed with Diabetes Mellitus
• Individuals with dyslipidemia on pharmacological treatment
• Individuals with hypertension on pharmacological treatment
• Smokers or heavy drinking individuals (>2-3 servings/day in men and > 1 serving/day in women (1 serving=1 glass of wine or 1 bottle of beer))
• Individuals with large weight fluctuations or who have undergone in recent months a weight loss diet
• Individuals with gastrointestinal diseases that affect the digestion or the absorption of nutrients
• Individuals receiving at least the preceding 2 months a pharmacological treatment that modifies the lipid profile (for example, statins, fibrates, diuretics, corticosteroids, oral antidiabetic medications)
• Pregnant or breastfeeding women
• Women with menstrual irregularities (absence of menstrual cycle at least 2 months prior)
• Individuals with intense physical activity

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Anhydrous Glucose	Anhydrous Glucose	1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
Quinoa variety 1	Quinoa variety 1	1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
Quinoa variety 3	Quinoa variety 3	1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
Quinoa variety 2	Quinoa variety 2	1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
Quinoa variety 4	Quinoa variety 4	1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.

Primary Outcome Measures

Name	Time	Method
Glycemic index	0, 15, 30, 45, 60, 90, 120 min	The glycemic index is calculated with the incremental area under the curve of the glycemic response 7 time points ( 0 , 15 , 30, 45 , 60, 90 , 120 min) to 50 g intake carbohydrate food test food and reference

Secondary Outcome Measures

Name	Time	Method
Glucose metabolism related parameters	day 1, 8, 15, 22, 29	glucose and insulin assessed in 7 point curves
satiety hunger assessment (visual analogue scale)	just before taking the product, just after taking the product, 30, 60 , 90, 120, 180, 240 min and 260 min after taking the product)	visual analogue scale to assessment satiety and hunger will be picked up in 9 time points to calculate the area under the curve to get a score
Weight	day 1, 8, 15, 22, 29	Weight
Adverse effects	day 1, 8, 15, 22, 29	symptoms of gastrointestinal intolerance (nausea, diarrhea, bloating or other gastrointestinal disorder
Blood hormonal markers	just before taking the product, 15, 30, 45, 60, 90 and 120 min after consuming the product	ghrelin, GLP-1 (glucagon-like peptide) and peptide YY
height	day 1, 8, 15, 22, 29
waist circumference	day 1, 8, 15, 22, 29
BMI	day 1, 8, 15, 22, 29	body mass index

Trial Locations

Locations (1)

Hospital Universitairo La Paz; 🇪🇸 Madrid, Spain